ArticleFrontiers in oncology2025
Integration of 2D/3D deep learning and radiomics for predicting lymphovascular invasion in T1-stage invasive lung adenocarcinoma: a multicenter study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Accurate prediction of the lymphovascular invasion (LVI) status in patients with T1-stage invasive lung adenocarcinoma (LUAD) is crucial for treatment decision-making. Currently, there is a lack of highly efficient and precise prediction models. Methods: In this retrospective study, 334 patients with T1-stage invasive LUAD who underwent radical surgery from four academic medical centers were included. Conventional radiomic features, two-dimensional deep learning (2D DL) features, and three-dimensional deep learning (3D DL) features were extracted from the tumor regions of the patients' CT images. Corresponding prediction models were constructed, and these features were integrated to develop a combined model for identifying the LVI status. The performance of the model was evaluated by calculating the area under the receiver operating characteristic (ROC) curve (AUC), and the net benefit of the models was compared using decision curve analysis (DCA). Results: The combined model demonstrated excellent performance in distinguishing the LVI status, with its predictive ability superior to that of individual models. The AUC values for the training set, internal validation set, and external test set reached 0.958 (95% CI: 0.9294 - 0.9863), 0.886 (95% CI: 0.7938 - 0.9786), and 0.884 (95% CI: 0.8277 - 0.9401), respectively. DCA showed that the net benefit provided by the combined model was higher than that of other radiomic models. Conclusions: The combined model integrating radiomics, 2D DL, and 3D DL exhibits excellent performance in predicting the LVI status of patients with T1-stage invasive LUAD, and can provide key information for clinical treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.